PharmaShots Weekly Snapshots (April 12 – 16, 2021)

ThermoFisher to Acquire PPD for ~$17.4B

Published: Apr 16, 2021 | Tags: ThermoFisher, Acquire, PPD, ~$17.4B

Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children

Published: Apr 16, 2021 | Tags: Roche, Evrysdi (risdiplam), Receives, Health Canada, Approval, Spinal Muscular Atrophy, Adults, Children

GSK Discontinues the P-II Trials of Feladilimab for Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Published: Apr 16, 2021 | Tags: GSK, Discontinues, P-II Trials, Feladilimab, Advanced, Metastatic, Head, Neck Squamous Cell Carcinoma

Omada Health Launches the First Virtual Cardiometabolic Clinic for Patients with Diabetes and Hypertension

Published: Apr 16, 2021 | Tags: Omada Health, Launches, First, Virtual, Cardiometabolic Clinic, Patients, Diabetes, Hypertension

Genentech Presents New Data of Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis at AAN2021

Published: Apr 16, 2021 | Tags: Genentech, Presents, New Data, Ocrevus (ocrelizumab), Relapsing, Primary, Progressive, Multiple Sclerosis

Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar, bevacizumab) in Russia

Published: Apr 16, 2021 | Tags: Prestige Biopharma, Pharmapark, Sign, Exclusive License, Supply Agreement, Commercialize, HD204, Russia

Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

Published: Apr 15, 2021 | Tags: Boehringer Ingelheim, MD Anderson, Expand, Collaboration, Accelerate, Targeted, Therapies, Lung Cancer

BMS’ Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC’s Approval for 1L Treatment of Advanced Renal Cell Carcinoma

Published: Apr 15, 2021 | Tags: BMS, Opdivo (nivolumab), Cabometyx (cabozantinib), Receive, EC, Approval, 1L, Treatment, Advanced, Renal Cell Carcinoma

Medtronic Launches World’s First Extended Insulin Infusion Set to Reduce Burden for People with Diabetes in Europe

Published: Apr 15, 2021 | Tags: Medtronic, Launches, World, First, Extended, Insulin Infusion Set, Reduce, Burden, People, Diabetes, Europe

Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

Published: Apr 15, 2021 | Tags: Genentech, Presents, Results, Two-Year Data, Evrysdi (risdiplam),  Infants, Type 1 SMA

AstraZeneca Collaborates with Sanguina to Develop AnemoCheck App for Hemoglobin Management in Patients with Anemia of CKD

Published: Apr 15, 2021 | Tags: AstraZeneca, Collaborates, Sanguina, Develop, AnemoCheck App,  Hemoglobin Management, Patients, Anemia, CKD

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

Published: Apr 15, 2021 | Tags: Eli Lilly, Signs, Exclusive, License Agreement, SciNeuro, Develop,  Commercialize, Alpha-synuclein, Targeted, Therapies, China

Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

Published: Apr 14, 2021 | Tags: Merck KGaA, Expand, Collaboration, NKMax, Evaluate, Combination, SNK01, Erbitux (cetuximab), Metastatic NSCLC

Innovent and Lilly Present Results of Tyvyt (sintilimab) in P-III ORIENT-3 Trial as 2L Treatment for Advanced or Metastatic Squamous NSCLC at AACR 2021

Published: Apr 14, 2021 | Tags: Innovent and Lilly, Present, Results, Tyvyt (sintilimab), P-III ORIENT-3 Trial, 2L, Treatment, Advanced, Metastatic Squamous NSCLC

Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies

Published: Apr 14, 2021 | Tags: Spark Therapeutics, Signs, Option Agreement, Senti Bio, Develop, Precision, Gene Therapies

AstraZeneca’s Tagrisso (osimertinib) Receives the NMPA’s Approval for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

Published: Apr 14, 2021 | Tags: AstraZeneca, Tagrisso (osimertinib), Receives, NMPA, Approval,  Adjuvant, Treatment, Patients, Early-Stage EGFR-Mutated Lung Cancer

Roche and Biocorp Launch Mallya Smart Insulin Pen for Patients with Diabetes in France

Published: Apr 14, 2021 | Tags: Roche and Biocorp, Launch, Mallya Smart Insulin Pen, Patients, Diabetes, France

J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

Published: Apr 14, 2021 | Tags: J&J, Pauses, Dosing, COVID-19 Vaccine, Blood Clotting

Avantor to Acquire Ritter and its Affiliates for ~$1.06B

Published: Apr 13, 2021 | Tags: Avantor, Acquire, Ritter, Affiliates, ~$1.06B

Sanofi Collaborates with C4XD for an Oral Therapy to Treat Inflammatory Diseases

Published: Apr 13, 2021 | Tags: Sanofi, Collaborates, C4XD, Oral Therapy, Treat, Inflammatory Diseases

DiaSorin to Acquire Luminex for ~$1.8B

Published: Apr 13, 2021 | Tags: DiaSorin, Acquire, Luminex, ~$1.8B

Sage and Biogen Report Results of SAGE-324 in P-II KINETIC Study for Essential Tremor

Published: Apr 13, 2021 | Tags: Sage and Biogen, Report, Results, SAGE-324, P-II KINETIC Study, Essential Tremor

Novartis’s Xolair (omalizumab) Prefilled Syringe for Self-Injection Receives the US FDA’s Approval Across All Indications

Published: Apr 13, 2021 | Tags: Novartis, Xolair (omalizumab), Prefilled Syringe, Self-Injection, Receives, US, FDA, Approval, Indications

Microsoft to Acquire Nuance for ~$19.7B

Published: Apr 13, 2021 | Tags: Microsoft, Acquire, Nuance, ~$19.7B

BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021

Published: Apr 12, 2021 | Tags: BMS, Presents, Results, Opdivo (nivolumab), CT, P-III CheckMate-816 Trial, Resectable NSCLC

Bayer Reports Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma

Published: Apr 12, 2021 | Tags: Bayer, Reports, Results, Aliqopa (copanlisib), Rituximab, P-III CHRONOS-3 Study, Relapsed Indolent Non-Hodgkin’s Lymphoma

Daiichi Sankyo Initiates P-II Trial of Pexidartinib for Tenosynovial Giant Cell Tumor in Japan

Published: Apr 12, 2021 | Tags: Daiichi Sankyo, Initiates, P-II Trial, Pexidartinib, Tenosynovial Giant Cell Tumor, Japan

AstraZeneca’s Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19

Published: Apr 12, 2021 | Tags: AstraZeneca, Farxiga (dapagliflozin), Fails, Meet, Primary Endpoint, P-III DARE-19 Trial, COVID 19

Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection

Published: Apr 12, 2021 | Tags: Roche, Report, Results, Ab Cocktail, P-III REGN-COV 2069 Trial, Symptomatic COVID 19 Infection

Sanofi to Acquire Tidal Therapeutics for ~$470M

Published: Apr 12, 2021 | Tags: Sanofi, Acquire, Tidal Therapeutics, ~$470M

Related Post: PharmaShots Weekly Snapshots (Apr 05 – 09, 2021)